Details of the Drug

General Information of Drug (ID: DMAC457)

Drug Name
LY3127804
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Therapeutic Class
Antiviral Agents
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D04KTI

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUMAN angiopoietin-2 (ANG-2) TT0APVH ANGP2_HUMAN Inhibitor [3]
Angiopoietin-2 (ANGPT2) TTKLQTJ ANGP2_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Coronavirus Disease 2019 (COVID-19)
ICD Disease Classification 1D6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Angiopoietin-2 (ANGPT2) DTT ANGPT2 3.47E-04 -0.31 -0.4
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04342897) A Study of LY3127804 in Participants With COVID-19. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Updates: Lilly's Global COVID-19 Response